These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15660122)

  • 1. Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan.
    Chrysant SG; Chrysant GS; Desai A
    J Hum Hypertens; 2005 Mar; 19(3):173-83. PubMed ID: 15660122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telmisartan provides superior BP reduction from morning to morning compared to other leading ARBs.
    Cardiovasc J S Afr; 2006; 17(4):210. PubMed ID: 17001428
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
    White WB; Lacourciere Y; Davidai G
    Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
    Serebruany VL; Atar D; Hanley DF
    Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
    [No Abstract]   [Full Text] [Related]  

  • 5. Circadian rhythm of blood pressure and the relation to cardiovascular events.
    Giles TD
    J Hypertens Suppl; 2006 Apr; 24(2):S11-6. PubMed ID: 16601555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardioprotective effects of telmisartan in uncomplicated and complicated hypertension.
    Grassi G; Quarti-Trevano F; Mancia G
    J Renin Angiotensin Aldosterone Syst; 2008 Jun; 9(2):66-74. PubMed ID: 18584582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy.
    Masuda S; Tamura K; Wakui H; Kanaoka T; Ohsawa M; Maeda A; Dejima T; Yanagi M; Azuma K; Umemura S
    Hypertens Res; 2009 Nov; 32(11):950-5. PubMed ID: 19713965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes.
    Cao Z; Cooper ME
    Acta Diabetol; 2012 Aug; 49(4):243-54. PubMed ID: 21947383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of stroke in patients with hypertension.
    Dahlöf B
    Am J Cardiol; 2007 Aug; 100(3A):17J-24J. PubMed ID: 17666193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
    Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
    Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials.
    Williams B; Lacourcière Y; Schumacher H; Gosse P; Neutel JM
    J Hum Hypertens; 2009 Sep; 23(9):610-9. PubMed ID: 19225530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring.
    Lacourcière Y; Neutel JM; Davidai G; Koval S
    Am J Hypertens; 2006 Jan; 19(1):104-12. PubMed ID: 16461201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertension treatment and implications of recent cardiovascular outcome trials.
    Weber MA
    J Hypertens Suppl; 2006 Apr; 24(2):S37-44. PubMed ID: 16601560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telmisartan 80 mg/hydrochlorothiazide 25 mg provides clinically relevant blood pressure reductions across baseline blood pressures.
    Neldam S; Schumacher H; Guthrie R
    Adv Ther; 2012 Apr; 29(4):327-38. PubMed ID: 22477543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective treatment of hypertension by AT(1) receptor antagonism: the past and future of telmisartan.
    Goebel M; Clemenz M; Unger T
    Expert Rev Cardiovasc Ther; 2006 Sep; 4(5):615-29. PubMed ID: 17081084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telmisartan in the treatment of hypertension in patients with chronic renal insufficiency.
    Weinbergová O; Metelka R; Vymetal J; Konecný K; Kosatíková Z
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2004 Jul; 148(1):69-73. PubMed ID: 15523550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan.
    Ucciferri C; Falasca K; Mancino P; Di Iorio A; Vecchiet J
    Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):491-8. PubMed ID: 22696876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of angiotensin II receptor blockers on relationships between 24-hour blood pressure, autonomic function, and health-related QOL.
    Okano Y; Tamura K; Kuji T; Masuda S; Tochikubo O; Umemura S
    Clin Exp Hypertens; 2009 May; 31(3):250-8. PubMed ID: 19387901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ONTARGET/TRANSCEND Trial Programme: baseline data.
    Sleight P
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S50-6. PubMed ID: 15868120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.